Recent Updates
Recently added Catalysts

Capecitabine orally days 1-21

Phase 1

Pancreatic Cancer | Small molecule | Oncology |Roche Holding AG|Trials Updated: Oct 14, 2016

Capecitabine orally days 1-21 target and mechanism

Molecular targetTYMS
Target classInhibitor
ModalitySmall molecule
ChEMBLCHEMBL1773

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDDMC
Total Trials1
Total Enrollment44

FDA Designations

No designations recorded

Capecitabine orally days 1-21 clinical trials

Capecitabine orally days 1-21 · 1 trial · 1 indication

Phase 1 1
NCT00260364Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic CancerPancreatic Cancer
COMPLETED44 Analytics
PHASE1COMPLETED
Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer
Pancreatic Cancer
NCT0026036444
Unlock trial analytics

Study Endpoints

Primary Endpoints

Part A (Phase I): Dose-limiting Toxicity (DLT)
Part B (Phase II): Overall response rate (complete response and partial response)

Secondary Endpoints

The secondary efficacy objectives of the trial are: One year survival and median overall survival
Progression free survival, Disease control rate.
The secondary safety objectives are: Toxicity,Quality of life
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Interventions

NameTypeDescription
Gemcitabine 1000 mg/m2 iv days 1, 8, 15 of a 28 day cycleDRUG -
Capecitabine orally days 1 -21DRUG -
Erlotinib 100 mg orally days 1-28DRUG -
Bevacizumab 5 mg/kg intravenously every 2 weeksDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed adenocarcinoma of the pancreas * Locally advanced or metastatic disease * Not amenable to curative resection * No invasion of adjacent organs (e.g., duodenum or stomach) by CT scan * Unidimensionally measurable disease as assessed...

Countries:United Kingdom
Unlock Eligibility Criteria

Competitive Landscape -Pancreatic Cancer 248 trials

Top 20 of 69 competitors

CompanyTickerTrialsLead PhaseDrugs
Revolution Medicines, Inc.RVMD12PHASE3Daraxonrasib, Zoldonrasib, Elironrasib, RMC-5127
Arcus Biosciences, Inc.RCUS2PHASE3Quemliclustat, Zimberelimab, Etrumadenant
Bristol-Myers Squibb CompanyBMY5PHASE2Navlimetostat, Nab-paclitaxel, Nivolumab, BMS-986340, Pumitamig
AbbVie, Inc.ABBV6PHASE2Telisotuzumab Adizutecan, ABBV-253, ABBV-400, Azirkitug, Budigalimab
Pfizer Inc.PFE7PHASE2tisotumab vedotin, Ponsegromab, PF-07934040, Bevacizumab, Sasanlimab
AstraZeneca PLCAZN9PHASE2AZD0901, FPI-2053, FPI-2107, FPI-2068, AZD4360
Merck & Co., Inc.MRK6PHASE2Belzutifan, Patritumab Deruxtecan, Pembrolizumab, Sacituzumab tirumotecan
Immuneering Corp. Class AIMRX2PHASE3Atebimetinib
BioNTech SE Sponsored ADRBNTX2PHASE2Autogene cevumeran, Pumitamig
Eli Lilly and CompanyLLY7PHASE1LY4101174, LY4066434, Cetuximab, Gemcitabine, Pemetrexed
Exelixis, Inc.EXEL1PHASE2Zanzalintinib
HUTCHMED (China) Limited Sponsored ADRHCM1PHASE2Surufatinib
Agenus Inc.AGEN4PHASE2AGEN1423, Botensilimab, Balstilimab, Zalifrelimab
Novartis AG Sponsored ADRNVS3PHASE2Spartalizumab, 68Ga-NNS309, Lu-NNS309, 177Lu-DFC413
ArriVent BioPharma, Inc.AVBP3PHASE2MRG007
Verastem, Inc.VSTM3PHASE2VS-7375, Avutometinib
ImmunityBio IncIBRX1PHASE2Nogapendekin alfa inbakicept, Aldoxorubicin, PD-L1 t-haNK
Jazz Pharmaceuticals Public Limited CompanyJAZZ1PHASE2Zanidatamab
Incyte CorporationINCY3PHASE2Ruxolitinib, Pemigatinib, Retifanlimab
Corcept Therapeutics Incorporated.CORT1PHASE2Relacorilant
Unlock Competitive Intelligence

Other drugs targeting TYMS

Pemetrexed LLY· PHASE3 pemetrexed disodium LLY· PHASE2 Capecitabine NVS· PHASE3 capecitabine RTD RHHBY· PHASE1

Explore more on BiopharmaWatch

Roche Holding AG (RHHBY)Pipeline, catalysts, financials, insiders and newsPancreatic Cancer disease mapEvery company developing for Pancreatic Cancer, by stage and capitalFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with CCompanies A to ZEvery biotech and pharma company we track